ARRDC3 and lymphoma: Having found that loss of Arrdc3 confers a competitive advantage in malignant Eμ-Myc lymphoma cells, and having generated an Arrdc3 knockout mouse model, we next investigated whether Arrdc3 might impact MYC-driven lymphoma development in vivo.